Aurinia Pharmaceuticals Inc. - 8-K Filing
Aurinia Pharmaceuticals raises 2026 revenue guidance to $325M-$330M following Q3 results showing 14% YoY total revenue growth. (Items: 2.02 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or)
Tickers: $AUPH